Navigating the Complexity of Infectious Disease Development

Infectious disease trials require careful planning around changing epidemiology, patient populations, site selection, and regional considerations. Novotech brings the experience and insight to help sponsors make informed decisions and execute studies effectively.

  • Expertise Where It Matters

    • Access to experienced infectious disease teams with therapeutic and clinical expertise
    • Local regulatory expertise in key infectious disease research markets
    • Established relationships with key opinion leaders, investigators, and research networks
  • Built for Infectious Disease Complexity

    • Support for complex infectious disease programs across diverse indications, therapeutic approaches, and patient populations
    • Expertise across development stages, from first-in-class programs and novel mechanisms to large-scale vaccine studies
    • Local teams in key infectious disease research markets to support study planning and execution
  • Global Clinical Trial Delivery

    • Support for therapies, vaccines, and prevention programs throughout development
    • Global delivery capabilities across Asia-Pacific, North America, and Europe
    • Regional knowledge and regulatory expertise supporting regional and global infectious disease programs
  • Early Development
    Through Approval

  • Global Regulatory &
    Operational Support

  • Therapies Reaching
    Patients

  • Quality & Compliance
    at Every Step

  • Scientific Excellence
    & Innovation

  • Data Integrity &
    Transparency

Our Infectious Disease Experience at a Glance

  • 443

    Infectious Diseases studies conducted

  • 872

    Investigators and key opinion leaders engaged

  • 1499

    Sites activated globally

  • 49

    Countries supporting clinical programs

  • 32371

    Patients enrolled

  • 54

    Indications supported

  • 24

    Vaccine studies

Our Infectious Diseases Advantage

Deep Infectious Disease Expertise

  • Dedicated infectious disease leadership and therapeutic expertise.
  • Experience across viral, bacterial, fungal, and emerging infectious diseases.
  • Expertise supporting complex infectious disease study designs; pioneering umbrella designs, platform studies and accelerated dosing structures.
  • Experience across small molecules, antibodies, vaccines, immunotherapies, RNA, cell and gene therapies.

Strategic Access to Key Research Markets

  • Deep roots in regions that account for a significant share of global infectious disease clinical research activity.
  • Access to diverse patient populations, specialist treatment centers, and established research networks.
  • Recognized world leading CRO in Hepatitis B research, with 130+ projects supported.

Global Development and Regulatory Expertise

  • Integrated delivery model supporting regional and global infectious disease programs.
  • Track record supporting infectious disease programs from early development to registration and post-marketing studies.
  • Global operational and regulatory expertise across major development markets.

Indication Experience

Hover over each indication to explore conditions studied

 
  • Blood and systemic infections Sepsis; Bacterial infections; Pyogenic bacterial infection; Staphylococcus aureus infection; Bacterial meningitis; Meningococcal disease; MRSA infection

  • Neurological infections Viral encephalitis; Bacterial meningitis; Meningitis; Meningococcal disease; Other encephalitis; Postherpetic polyneuropathy

  • Respiratory infections Human RSV infection; Whooping cough; Pneumonia; Viral pneumonia; Bronchitis; Acute bronchitis; Upper respiratory tract infection; Acute nasopharyngitis; Acute otitis media; Other respiratory infections

  • Maternal, neonatal and reproductive infections Vulvovaginal candidiasis; Chlamydia; Genital warts; Other reproductive tract infections

  • Sexually transmitted infections Chlamydia; Genital warts; Sexually transmitted infections; Other STIs

  • Skin and soft tissue infections Herpes simplex infection; Chickenpox; Shingles/Zoster; Mpox; Infectious viral skin disease; Skin lesions; Other skin and soft tissue infections

  • Parasitic infections Malaria; Hookworm disease; Schistosomiasis; Head lice; Other parasitic diseases

  • Fungal infections Candidiasis; Vulvovaginal candidiasis; Fungal infections; Invasive aspergillosis; Other invasive fungal infections

  • Vector-borne diseases Malaria; Dengue; Zika virus disease; Chikungunya virus infection; Yellow fever; Lassa fever; Other vector-borne diseases

  • Gastrointestinal infections Gastroenteritis; Enteritis due to Norovirus; Enterocolitis; Cholera; Other gastrointestinal infections

  • Bacterial infections Tuberculosis; Respiratory tuberculosis; Typhoid; Staphylococcus aureus infection; Group A streptococcal infection; Bacterial infection; Other bacterial infections

  • Liver infections Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Viral hepatitis complications; Other liver-associated infectious indications

  • Viral infections COVID-19; Influenza; HIV infection; Cytomegaloviral infection; Zika virus disease; Adenovirus infection; Varicella zoster virus infection; Human RSV infection; Other viral infections

  • Zoonotic infections Rabies; Ebola disease; Henipavirus encephalitis; Other zoonotic diseases

The Global Leader in Hepatitis Research

Our hepatitis experience spans a broad range of development programs, study settings, and therapeutic approaches.

Experience Across Hepatitis Treatment Modalities

Our experience includes interventional studies across NAs, RNAi, CpAMs, HBsAg release inhibitors, monoclonal antibodies, cccDNA inhibitors, immunomodulators, T-cell therapies, checkpoint inhibitors, vaccines, and advanced therapies.

130+ Hepatitis projects for 37 sponsors
500+ Hepatitis research sites, including KOLs and PIs
20+ Active hepatitis studies

Dedicated Expertise in Vaccine Development

The Vaccine Strategic Delivery Unit provides focused clinical and operational support for vaccine programs, bringing together specialists across functions and regions to address the specific demands of vaccine trials.

From study planning through execution, the team works to anticipate challenges, support efficient delivery, and maintain a consistent focus on study quality and the needs of sponsors, sites, and patients.

24 Vaccine studies supported

Emerging Infectious Disease Therapeutic Approaches

Infectious disease expertise and global operational capabilities support programs across a range of therapeutic and prevention approaches.

  • Vaccines

    • Prophylactic vaccines
    • Therapeutic vaccines
    • Novel administration routes
    • Pandemic preparedness programs
  • Antiviral Innovation

    • Long-acting antivirals
    • RNAi based therapies
    • Gene Editors
    • Epigenomic Silencers
  • Immune-Based Therapies

    • Immune-modulating therapies
    • Mono- and Poly-clonal antibodies
    • Checkpoint inhibitors
    • Cytokine and Antagonist Modulators

Expertise That Guides Infectious Disease Development

Our infectious disease leadership brings extensive therapeutic, clinical, and operational experience to help sponsors make informed development decisions and successfully execute trials across regions.